Csl Behring

This study tested a monthly injection called garadacimab to prevent sudden swelling attacks in children aged 2 to 11 with hereditary angioedema (HAE). The goal was to see if the drug is safe and reduces how often attacks happen. 22 children took part, and researchers tracked side…

This phase 3 trial tested a one-time gene therapy (AMT-061) in 67 adults with severe or moderately severe hemophilia B. The treatment uses a harmless virus to deliver a working gene for factor IX, a clotting protein. The goal was to reduce bleeding episodes and the need for regul…

This study tested a drug called garadacimab (CSL312) for long-term prevention of hereditary angioedema (HAE) attacks, which cause painful swelling. 171 people aged 12 and older received regular injections. The goal was to see if the drug is safe and reduces attack frequency over …

This study tested whether a protein called alpha-1 antitrypsin can prevent acute graft-versus-host disease (aGVHD) in people receiving a blood stem cell transplant for blood cancers like leukemia or lymphoma. The trial involved 222 participants aged 12 and older. The main goal wa…

This early-stage study tested a new drug called CSL040 in 62 healthy adults to see if it is safe and how the body processes it. The goal was to gather basic safety information before testing it in people with complement-mediated disorders. No treatment was given—just single or mu…

This study looked at how taking a new drug called vamifeport with or without food changes the amount that gets into the blood. Twenty-eight healthy adults aged 18 to 60 took part. The goal was simply to measure drug levels, not to treat any disease.